Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 10, 2026

Teradata Reports Fourth Quarter and Full-Year 2025 Financial Results

View original at finance.yahoo.com
Teradata Reports Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter Total ARR of $1.522 billion, an increase of 3% as reported and 1% in constant currency from the prior year period(1) Fourth quarter Recurring Revenue of $367 million, up 5% as reported and 3% in constant currency(1) Fourth quarter GAAP…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Our full-year results demonstrate strong operational discipline and establish a solid foundation as we enter 2026

    80% confidence
  • We have confidence in our agentic AI-fueled future

    80% confidence
  • Total ARR growth expected to be 2% to 4% year-over-year for full-year 2026

    80% confidence
  • Recurring revenue expected in the range of 6% to 8% year-over-year for Q1 2026

    80% confidence
  • Teradata's Autonomous AI and Knowledge platform is soundly resonating with customers; they recognize that the strengths we have built over decades are ideal for today's market needs

    80% confidence
  • Non-GAAP diluted EPS expected to be in the range of $2.55 to $2.65 per share for full-year 2026

    80% confidence
  • Free cash flow expected to be $310 million to $330 million for full-year 2026

    80% confidence
  • Our differentiated performance, scale, and hybrid capabilities, supported by our AI services, are proving to be a valuable combination

    80% confidence
  • Teradata delivered another set of strong results in the 4th quarter, as we again exceeded expectations for Total Revenue, Recurring Revenue and Free Cash Flow

    80% confidence
  • Recurring revenue expected in the range of flat to 2% year-over-year for full-year 2026

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com